 |
|---|
| As Of | Filer | Filing¹ | For·On·As | Docs:Size | Issuer | | Filing Agent | | | | | | | | | |
|---|
|
|---|
4/19/22 Reva Capital Markets LLC FOCUSN 12/31/21 1:2K SEC #7
4/19/22‡ FT 10051 EFFECT 4/19/22 1:2K SEC #5
4/19/22‡ CNH Capital Receivables LLC EFFECT 4/19/22 1:2K SEC #5
4/19/22‡ Foghorn Therapeutics Inc. EFFECT 4/19/22 1:2K SEC #5
4/19/22‡ Altamira Therapeutics Ltd. EFFECT 4/19/22 1:2K SEC #5
4/19/22‡ Modular Medical, Inc. EFFECT 4/19/22 1:2K SEC #5
4/19/22‡ HTG Molecular Diagnostics, Inc. EFFECT 4/19/22 1:2K SEC #5
4/19/22‡ AdTheorent Holding Co., Inc. EFFECT 4/19/22 1:2K SEC #5
4/19/22‡ FT 10091 EFFECT 4/19/22 1:2K SEC #5
4/19/22‡ indie Semiconductor, Inc. EFFECT 4/19/22 1:2K SEC #5
4/19/22‡ Qualtrics International Inc. EFFECT 4/19/22 1:2K SEC #5
4/19/22‡ Yotta Acquisition Corp. EFFECT 4/19/22 1:2K SEC #5
4/19/22‡ Cingulate Inc. EFFECT 4/19/22 1:2K SEC #5
4/19/22‡ Edesa Biotech, Inc. EFFECT 4/19/22 1:2K SEC #5
4/19/22‡ indie Semiconductor, Inc. EFFECT 4/19/22 1:2K SEC #5
4/19/22‡ Inspira Techs OXY B.H.N. Ltd. EFFECT 4/19/22 1:2K SEC #5
4/19/22‡ Lincoln Var Ins Products Trust EFFECT 4/19/22 1:7K SEC #5
→ LVIP BlackRock Advantage Allocation Fund
→ LVIP BlackRock Global Allocation Fund
→ LVIP Franklin Templeton Multi-Asset Opportunities Fund
4/19/22‡ Advent Techs Holdings, Inc. EFFECT 4/19/22 1:2K SEC #5
4/19/22‡ NRX Pharmaceuticals, Inc. EFFECT 4/19/22 1:2K SEC #5
4/19/22‡ Biolargo, Inc. EFFECT 4/19/22 1:2K SEC #5
| ____________ | | ‡ | A non-Insider-Ownership Filing that was accepted after the SEC “closed” at 5:30:00pm ET. The legal “Filed As Of” date may be the next, or another, day. | | ¹ | Filing/Form Types: | | EFFECT | SEC Notice of Effectiveness. | | FOCUSN | Annual Audit Report on a Financial Report [ a.k.a. FOCUS Report ] by a Broker or Dealer. | | → | Fund / Series: Fund or Series of this Filer with a Class or Contract that this Filing pertains to. |
|
